A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms verITI-8 Study
- Sponsors Bioverativ
- 02 Aug 2018 Planned End Date changed from 1 Dec 2020 to 1 Nov 2020.
- 02 Aug 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Nov 2020.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.